AMX-30SA法国
如果支持我的工作，请帮忙领取支付宝红包
“目录号: HY-14814
- 名称：AMX-30SA 30毫米双管自行高射炮
- 研发单位：武器研究与制造局
- 口径：小口径炮
免费账号
注册后每月签到一次可获得1G流量，不要在网站购买，需要节点私聊我
Anti-infection-
技术数据
- 口径：30毫米
- 总重：35,000千克
法国武器研究与制造局研制的口径30毫米的双管自行式高射炮。1975年生产，出口沙特阿拉伯。
客户端
Android
Windows
密码：1111
Delafloxacin (RX-3341, ABT-492)是氟喹诺酮类抗生素。
结构特点
该炮由30毫米自动炮，TG230A式炮塔，AMX-30坦克底盘，“绿眼”雷达，光学瞄准具和火控计算机等组成。主要构造均与AMX-13DCA30毫米双管自行高射炮相同。
使用教程
Android
Windows
Linux
Bacterial
主要用户
- 沙特阿拉伯
相关产品
G-418
disulfate-Anisomycin-Salinomycin-Avibactam
sodium-Vancomycin
hydrochloride-Hygromycin
B-Bleomycin
sulfate-Ciprofloxacin-Minocycline
hydrochloride-Ampicillin
sodium-Tetracycline
hydrochloride-Tebipenem-Kanamycin
sulfate-Solithromycin-Tedizolid-
生物活性
Description
Delafloxacin (RX-3341, ABT-492) is a fluoroquinolone antibiotic
agent.IC50 Value: MICs ranging from 0.0078 to 0.125 micro g/ml for
levofloxacin-resistant Streptococcus pneumoniae strains [1]Target:
AntibacterialABT-492 was more potent against quinolone-susceptible and
-resistant gram-positive organisms, had activity similar to that of
ciprofloxacin against certain members of the family Enterobacteriaceae,
and had comparable activity against quinolone-susceptible,
nonfermentative, gram-negative organisms.in vitro: ABT-492 exhibited
excellent in vitro activities against all 326 aerobic and anaerobic
antral puncture sinus isolates tested with MICs (in micrograms per
milliliter) at which 90% of the isolates tested were inhibited as
follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008;
and Streptococcus pneumoniae, 0.015 [2]. ABT-492 was as active as
trovafloxacin against Chlamydia trachomatis, indicating good
intracellular penetration and antibacterial activity [3].in vivo:
Clinical trial: N/A
Clinical Trial
NCT02505997
Melinta Therapeutics, Inc.
VA Drug Interactions
June 2015
Phase 1
NCT02245243
Melinta Therapeutics, Inc.
Hepatic Impairment
September 2014
Phase 1
NCT02679573
Melinta Therapeutics, Inc.
Community Acquired Bacterial Pneumonia
December 14, 2016
Phase 3
NCT02015637
Melinta Therapeutics, Inc.
Gonorrhea
January 2014
Phase 3
NCT01984684
Melinta Therapeutics, Inc.
Skin and Subcutaneous Tissue Bacterial Infections-Skin Structures and
Soft Tissue Infections
May 2014
Phase 3
NCT01811732
Melinta Therapeutics, Inc.
Skin and Subcutaneous Tissue Bacterial Infections
April 2013
Phase 3
NCT01283581
Melinta Therapeutics, Inc.
Skin and Subcutaneous Tissue Bacterial Infections
January 2011
Phase 2
NCT00719810
Melinta Therapeutics, Inc.
Skin Structure Infections-Bacterial Skin Diseases-Staphylococcal Skin
Infections
June 2008
Phase 2
View MoreCollapse
References
[1].Gunderson SM, Hayes RA, Quinn JP, In vitro pharmacodynamic
activities of ABT-492, a novel quinolone, compared to those of
levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae,
and Moraxella catarrhalis. Antimicrob Agents Chemother. 2004
Jan;48(1):203-8.
[2].Goldstein EJ, Citron DM, Merriam CV, In vitro activities of
ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic
pathogens isolated from antral sinus puncture specimens from patients
with sinusitis. Antimicrob Agents Chemother. 2003
Sep;47(9):3008-11.
[3].Nilius AM, Shen LL, Hensey-Rudloff D, In vitro antibacterial
potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob
Agents Chemother. 2003
Oct;47(10):3260-9.